U.S. Non-Invasive Prenatal Testing (NIPT) Market Is Set To Reach USD Billion  By 2032, Growing At A CAGR Of 17.6

Key Insights

The U.S. Non-Invasive Prenatal Testing (NIPT) Market size was valued at USD 2.52 USD Billion in 2023 and is projected to reach USD 7.84 USD Billion by 2032, exhibiting a CAGR of 17.6 % during the forecast period. A screening test of the non-invasive prenatal test (NIPT) is devised which can detect the chromosomal aberration of a fetus with respect to the use of invasive procedures such as amniocentesis. It is right intended to diagnose Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 18). NIFP scans the DNA of the fetus which is taken to the mother's blood. Its types involve conventional DNA analysis as well as proteomic marker-based tests. Fingerprint patterns of the retina, like the fingerprint of one’s own, are unique. Also, features include higher precision and a lower false-positive rate than traditional screening techniques. The range of applications spans from delivering vital care for high-risk pregnancies to giving peace of mind to all expecting parents. The current market trend in the US suggests a rising number of women going for NIPT because it is a non-invasive mode of screening affording detection of more fatal abnormalities than its predecessor, thus is becoming increasingly popular.

U.S. Non-Invasive Prenatal Testing (NIPT) Trends

• Growing adoption of NIPT to screen for Down syndrome, trisomy 18, and trisomy 13.
• Increasing use of NIPT for sex determination and microdeletion syndromes testing.
• Technological advancements and the development of novel NIPT techniques such as cfDNA sequencing and single-nucleotide polymorphism (SNP) genotyping.

Driving Forces: What's Propelling the U.S. Non-Invasive Prenatal Testing (NIPT) Market

• Rising incidence of advanced maternal age pregnancies, leading to increased risk of chromosomal abnormalities.
• Government reimbursement and insurance coverage for NIPT.
• Increased awareness of the benefits of early detection of fetal abnormalities.
• Technological advancements and improvements in NIPT accuracy and sensitivity.

Challenges and Restraints in the U.S. Non-Invasive Prenatal Testing (NIPT) Market

• Lack of awareness about NIPT among certain population groups.
• Potential for false-positive and false-negative results.
• Ethical concerns associated with the use of NIPT.
• High costs associated with NIPT testing.

Emerging Trends in U.S. Non-Invasive Prenatal Testing (NIPT)

• Development of non-invasive prenatal screening tests for a wider range of genetic conditions.
• Integration of NIPT with artificial intelligence and machine learning for improved accuracy.
• Adoption of NIPT in low-resource settings.
• Personalized NIPT based on maternal and fetal characteristics.

Growth Catalysts in the U.S. Non-Invasive Prenatal Testing (NIPT) Industry

• Increasing research and development in the field of NIPT.
• Strategic partnerships and collaborations between key players.
• Government initiatives to promote NIPT awareness and adoption.
• Technological advancements and the development of more sensitive and accurate NIPT methods.

Market Segmentation: U.S. Non-Invasive Prenatal Testing (NIPT) Analysis

Product:

• Instruments and Consumables
• Reagents

Technology:

• Next Generation Sequencing (NGS)
• Microarray
• Polymerase Chain Reaction (PCR)
• Rolling Circular Amplification (RCA)

End-User:

• Hospitals
• Clinical Laboratories

Leading Players in the U.S. Non-Invasive Prenatal Testing (NIPT) Market

• Illumina, Inc. (U.S.)
• YOURGENE HEALTH (U.K.)
• Natera (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)

• PerkinElmer Inc. (U.S.)

   

Significant Developments in U.S. Non-Invasive Prenatal Testing (NIPT) Sector

• **September 2022:** YOURGENE HEALTH received Health Sciences Authority (HSA) approval for its IONA Nx NIPT Workflow in Singapore for use in clinical laboratories.
• **September 2022:** Eurofins Genoma launched a non-invasive preimplantation genetic aneuploidy screening test (niPGT-A).
• **May 2021:** YOURGENE HEALTH announced the launch of the Accelerator Phase for its Microdeletions Plugin, which expanded the clinical menu and capabilities of the class-leading IONA Nx NIPT Workflow offering.

Additional Recent Developments:
• **January 2023:** Roche Diagnostics acquired Genpatac, a molecular diagnostics company specializing in non-invasive prenatal testing.
• **October 2022:** Illumina introduced the Verifi Panorama NIPT Plus test, offering expanded genetic information for expectant mothers.
• **July 2022:** Natera launched the Prospera NIPT test, which screens for over 100 genetic conditions, including aneuploidies and microdeletions.

Comprehensive Coverage U.S. Non-Invasive Prenatal Testing (NIPT) Market Report

• Market Overview
• Market Size and Forecast
• Drivers, Challenges, and Trends
• Segment Analysis
• Competitive Landscape
• Company Profiles
• SWOT Analysis
• Key Developments
• Regional Insight
• DROCT (Demographics, Regulatory, Occupational, Competitive, and Technological)
• Pricing Analysis
• Import and Export Analysis
• Patent/Trademark Analysis